A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study

• Sponsor: National Heart, Lung, and Blood Institute (NHLBI) (NIH)
• Overall Status: Completed
• CT.gov ID: NCT00340509
• Collaborator: (none)
• Enrollment: 1,888
• Location: 1
• Duration (Months): 140.9
• Patients Per Site Per Month: 13.4

Study Details

Study Description

Brief Summary

Studies have shown that there is a significant association between serum bilirubin concentrations and risk of coronary artery disease (CAD). So far, no linkage analysis in humans between serum bilirubin and DNA markers has been reported. The purpose of this protocol is to identify chromosome regions that contain quantitative trait loci (QTL) involved in serum bilirubin metabolism and bilirubin concentration. In the Framingham Study, a 10cM genome scan (about 400 markers) has been conducted in more than three hundred families. Serum bilirubin was measured in the first and second exams of the Framingham Offspring. These data provide us the opportunity to undertake linkage analyses to map QTL of serum bilirubin.

Condition or Disease	Intervention/Treatment	Phase
Genetics

Detailed Description

Many studies showed that there is a significant relationship between serum bilirubin levels and risk of coronary artery disease (CAD). We carried out a genome-wide scan for quantitative trait loci of serum bilirubin through the 330 extended Framingham families and found significant evidence of linkage of serum bilirubin to chromosome 2q telomere where an important candidate gene, Uridine diphosphate glycosyltransferase 1 gene (UGT1A1), resides. The purposes of this protocol are to confirm linkage between serum bilirubin and UGT1A1, mathematical modeling and association studies between the genotypes of UGT1A1 and CAD.

Study Design

• Study Type: Observational
• Actual Enrollment: 1888 participants
• Official Title: A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study
• Study Start Date: Oct 26, 2001
• Study Completion Date: Jul 23, 2013

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

• INCLUSION CRITERIA:

The study population will include the members of the 330 Framingham Study families and 1888 random individuals.

The Original Cohort will also be included.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National Heart, Lung and Blood Institute (NHLBI), 9000 Rockville Pike	Bethesda	Maryland	United States	20892

Sponsors and Collaborators

• National Heart, Lung, and Blood Institute (NHLBI)

Investigators

• Principal Investigator: Gang PH Zheng, Ph.D., National Heart, Lung, and Blood Institute (NHLBI)

Study Documents (Full-Text)

None provided.

More Information

Publications

• Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998 May;62(5):1198-211.
• Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem. 1995 Oct;41(10):1504-8.
• Djoussé L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol. 2001 May 15;87(10):1196-200; A4, 7.

• ClinicalTrials.gov Identifier: NCT00340509
• Other Study ID Numbers: 999902016; 02-H-N016
• First Posted: Jun 21, 2006
• Last Update Posted: Dec 16, 2019
• Last Verified: Jul 23, 2013

• Keywords provided by , ,: Genetics; Population; CHD Risk; Epidemiology; Gene Mapping

Study Results

No Results Posted as of Dec 16, 2019